Actively Recruiting
IDOV-Immune for Advanced Solid Tumors
Led by ViroMissile, Inc. · Updated on 2026-03-02
78
Participants Needed
6
Research Sites
92 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor. The purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors. Participants will receive a single intravenous (IV) infusion of IDOV-Immune and will be closely monitored for side effects and any changes in their cancer. This study is being conducted at multiple sites in the United States and Australia.
CONDITIONS
Official Title
IDOV-Immune for Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age �3E= 18 years
- Histologically or cytologically confirmed advanced solid tumors that have progressed despite standard therapy or have no standard therapy
- ECOG performance status �3C= 1
- Measurable disease as per RECIST v1.1
- Adequate organ and bone marrow function
- At least 28 days since major surgery, prior immunotherapy, or radiotherapy (except minor procedures)
- Negative pregnancy test for women of childbearing potential
- Agreement to use effective contraception during treatment and for 3 months after
- Ability to provide informed consent and comply with study requirements
You will not qualify if you...
- Prior treatment with an oncolytic virus
- Active or recent vaccinia virus infection or smallpox/monkeypox vaccination within 10 years
- Active uncontrolled infection requiring systemic treatment
- History of hepatitis B, hepatitis C, or HIV (unless meeting protocol-specific criteria)
- Unresolved �3E= Grade 2 toxicities from prior therapies (except hair loss or stable chronic conditions)
- Active or symptomatic autoimmune disease requiring systemic therapy
- Active or untreated CNS metastases (unless stable per protocol)
- Significant cardiac disease (e.g., NYHA Class III/IV heart failure)
- Interstitial lung disease or prior pneumonitis requiring steroids
- Conditions requiring chronic immunosuppressive therapy
- Severe skin disorders or history of pancreatitis
- Bleeding disorders or recent serious thromboembolic events
- Any medical or psychiatric condition that could interfere with study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110
Not Yet Recruiting
2
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Not Yet Recruiting
3
South Texas Accelerated Research Therapeutics
San Antonio, Texas, United States, 78229
Actively Recruiting
4
Royal North Shore Hospital
Saint Leonards, New South Wales, Australia, 2065
Not Yet Recruiting
5
Westmead Hospital
Westmead, New South Wales, Australia, 2145
Actively Recruiting
6
The Alfred Hospital
Melbourne, Victoria, Australia, 3004
Actively Recruiting
Research Team
C
Clinical Development
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here